Ablynx

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
Master of Science, Radiopharmaceutical, Procter & Gamble, Ablynx, Ghent University, Patient, SAN, Management

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors.

Key Points: 
  • SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors.
  • I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full potential of this emerging modality,” said Tim.
  • Tim Van Hauwermeiren co-founded argenx and has served as Chief Executive Officer since 2008.
  • “I am thrilled to welcome Tim to our board of directors,” said Ken Song, M.D., President and CEO of RayzeBio.

Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors

Retrieved on: 
Thursday, September 21, 2023
Partnership, G protein-coupled receptor, Iochpe-Maxion, Biotechnology, Roger W. Jones Award for Executive Leadership, Almirall, Antibody, USD, BGF, NED, Immunocore, GPCR, Partner, Patient, CBO, Chairperson, Drug discovery, Growth, Ablynx, Therapy, Eva-Lotta Kiibus, Chronic pain, Eurosport 1, Nomination, Management

Eva-Lotta Allan, Chair, Board of Directors, Maxion Therapeutics, commented: "I'm delighted to be appointed to Maxion at such an exciting time in its development.

Key Points: 
  • Eva-Lotta Allan, Chair, Board of Directors, Maxion Therapeutics, commented: "I'm delighted to be appointed to Maxion at such an exciting time in its development.
  • I look forward to working with the Board of Directors and the rest of the Maxion team to help improve patients' lives while creating value for our shareholders."
  • KnotBody technology combines the benefits of naturally occurring mini-proteins, which have ion channel modulating activity, with antibodies, using state-of-the-art phage and mammalian display technologies.
  • The resulting fusion protein, which combines the drug-like benefits of both molecules, helps address key challenges in ion channel and GPCR drug discovery.

COGNANO, Inc.: Statistical Discovery of Triple-negative Breast Cancer-specific Antibodies From a Huge Database Obtained by Alpaca Immunization

Retrieved on: 
Wednesday, March 1, 2023
Software, Research, Pharmaceutical, Oncology, Data Management, Consumer, Technology, Genetics, Science, Women, Biotechnology, Health, Death, Tissue, Malignancy, VHH, Life expectancy, Protein, Cancer, Coronavirus, Communication, Diagnosis, Immune system, Triple-negative breast cancer, EGFR, Breast cancer, Pancreatic cancer, VH, Library, Engineering, Drug discovery, Biomarker, Mining, OX40, Prognosis, Patient, Database, Hook effect, Sarcoma, TNBC, BioRxiv, B cell, Breast, Human, Immortalised cell line, SPIKE, Variable, Immunity, Antibody, Multimedia, Messenger, PGR, ER, Ablynx, Sanofi, Woman, Animal, Communications Biology, Vaccine, Glioblastoma, Cholangiocarcinoma

COGNANO, Inc. (Kyoto, Japan) and associates announced the discovery of a panel of antibodies specific for triple-negative breast cancer (TNBC).

Key Points: 
  • COGNANO, Inc. (Kyoto, Japan) and associates announced the discovery of a panel of antibodies specific for triple-negative breast cancer (TNBC).
  • The authors obtained a panel of antibodies indicating TNBC cancer cells through a computational approach using the genetic database from immunized alpacas.
  • Title: Statistical mining of triple-negative breast cancer-specific nanobodies among huge libraries from immunized alpacas.
  • In parallel, they identified rare TNBC biomarkers from its database by constructing a huge library of gene that encodes antibodies that recognize cancer cells.

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

Retrieved on: 
Wednesday, December 14, 2022
Inflammatory arthritis, MIRA, PASI, Veni, vidi, vici, Security (finance), Psoriatic arthritis, Adalimumab, Fatigue, Health assessment, Severity, Ageing, Research, ACR, Psoriasis Area and Severity Index, American College of Rheumatology, Inflammation, American College, Safety, Skin, Pain, Chemokine, Disability, Psoriasis, Moonlake, Securities and Exchange Commission (Philippines), Quality of life, VHH, Temperature, Trial of the century, Joint, KDA, Disease, Tissue, Patient, Swelling, Single-domain antibody, Antibody, ARGO, Hidradenitis suppurativa, Pharmaceutical industry, Vaccine, Oyster, Medical imaging, Sanofi, Ablynx

Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: “We are very pleased to have begun the ARGO study of the Nanobody sonelokimab in the treatment of psoriatic arthritis.

Key Points: 
  • Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: “We are very pleased to have begun the ARGO study of the Nanobody sonelokimab in the treatment of psoriatic arthritis.
  • The study will comprise approximately 200 patients, and will evaluate different doses of sonelokimab, with placebo control and adalimumab as an active reference arm.
  • Sonelokimab has been assessed in a randomized, placebo-controlled Phase 2b study in 313 patients with moderate-to-severe plaque-type psoriasis.
  • Psoriatic arthritis (PsA) is a chronic and progressive inflammatory arthritis associated with psoriasis primarily affecting the peripheral joints.

LabGenius Wins Government Innovation Grant to Support the Development of ML-driven Cancer Therapies

Retrieved on: 
Wednesday, November 30, 2022
Technology, Professional Services, Medical Supplies, Biotechnology, Other Manufacturing, Alternative Medicine, Health, Robotics, Health Technology, Manufacturing, Software, Other Professional Services, Radiology, Pharmaceutical, Finance, Venture Capital, Oncology, Multimedia, BMC, Machine learning, Therapy, Innovate UK, Synthetic biology, EVA, Innovation, Government, Immunotherapy, Pharmaceutical industry, Vaccine, Ablynx

With this recent grant, LabGenius has secured a total of over 1 million in government backing this year.

Key Points: 
  • With this recent grant, LabGenius has secured a total of over 1 million in government backing this year.
  • View the full release here: https://www.businesswire.com/news/home/20221130005020/en/
    LabGenius is pioneering the development of an ML-driven protein engineering platform (EVA).
  • This grant will be used to support the development of LabGenius pipeline of antibody therapeutics by financing the discovery of best-in-class immune cell engager molecules with favourable selective killing profiles.
  • This grant will enhance LabGenius ability to optimise an important class of immunotherapeutics and help us to accelerate drug candidates towards the clinic.

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

Retrieved on: 
Monday, November 14, 2022
Dermatology Life Quality Index, Clinical trial, MIRA, Abscess, Safety, Dermatology, Disease, Severity, Chemokine, Antibody, Prevalence, Investment, Health assessment, Moonlake, American College, Research, Inflammation, Pain, Adalimumab, Psoriasis Area and Severity Index, VHH, Patient, FDA, Rheumatology, Psoriasis, KDA, SLK, ARGO, Veni, vidi, vici, Skin, IRB, American College of Rheumatology, Temperature, Bimekizumab, Tissue, ACR, Numerical, Secukinumab, Pharmaceutical industry, Oyster, Medical imaging, Video game, HS, Ablynx, Psoriatic arthritis, Sanofi

Research and development expenses for the quarter ended September30, 2022, were $9.0 million, as compared to $11.4 million in the previous quarter.

Key Points: 
  • Research and development expenses for the quarter ended September30, 2022, were $9.0 million, as compared to $11.4 million in the previous quarter.
  • General and administrative expenses for the quarter ended September30, 2022, were $5.7 million, as compared to $6.3 million in the previous quarter.
  • Net loss for the quarter ended September30, 2022, was $14.7 million, compared to $17.4 million in the previous quarter.
  • MoonLake Immunotherapeutics AG, subsidiary of MoonLake Immunotherapeutics, was founded in 2021 and is headquartered in Zug, Switzerland.

Tethis appoints Holger Neecke as the company's Chief Executive Officer

Retrieved on: 
Thursday, October 20, 2022
Transfer, Doctor of Philosophy, Technology transfer, University technology transfer offices, Workflow, Patient, MBA, Business, Multimedia, Aptalis, Cancer, Technology, Company, Industry, Board, Blood, Liquid biopsy, SBS, Board of directors, Plasma, Head, MolMed, Biomarker, View, Management, Medical imaging, Online shopping, Ablynx

MILAN, Oct. 20, 2022 /PRNewswire/ -- Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announces the appointment of Mr Holger Neecke as the company's Chief Executive Officer.

Key Points: 
  • MILAN, Oct. 20, 2022 /PRNewswire/ -- Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announces the appointment of Mr Holger Neecke as the company's Chief Executive Officer.
  • Holger Neecke, Ph.D., MBA, is a molecular biologist with over 20 years of experience in the life sciences industry, specifically in pharma business development.
  • "Liquid Biopsy is revolutionizing cancer diagnostics" said Mr Neecke "and Tethis is uniquely positioned in this exciting market.
  • The entire Board of Directors is grateful for his dedication over the years as investor, Board member, Chairman and Chief Executive Officer of the Company.

Tethis appoints Holger Neecke as the company's Chief Executive Officer

Retrieved on: 
Thursday, October 20, 2022
Transfer, Doctor of Philosophy, Technology transfer, University technology transfer offices, Workflow, Patient, MBA, Business, Aptalis, Cancer, Technology, Company, Industry, Board, Blood, Liquid biopsy, SBS, Board of directors, Plasma, Head, MolMed, Biomarker, Management, Medical imaging, Ablynx

MILAN, Oct. 20, 2022 /PRNewswire/ -- Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announces the appointment of Mr Holger Neecke as the company's Chief Executive Officer.

Key Points: 
  • MILAN, Oct. 20, 2022 /PRNewswire/ -- Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announces the appointment of Mr Holger Neecke as the company's Chief Executive Officer.
  • Holger Neecke, Ph.D., MBA, is a molecular biologist with over 20 years of experience in the life sciences industry, specifically in pharma business development.
  • "Liquid Biopsy is revolutionizing cancer diagnostics" said Mr Neecke "and Tethis is uniquely positioned in this exciting market.
  • The entire Board of Directors is grateful for his dedication over the years as investor, Board member, Chairman and Chief Executive Officer of the Company.

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Retrieved on: 
Monday, September 26, 2022
Adult, Safety, Patient, ARGO, Psoriasis Area and Severity Index, Psoriatic arthritis, Research, Inflammation, Adalimumab, Hidradenitis suppurativa, Joint, Disease, Disability, Temperature, American College, Food, VHH, Antibody, Severity, Pain, Ageing, Skin, Veni, vidi, vici, Food and Drug Administration, 40, Trial of the century, Moonlake, PASI, Chemokine, Forward-looking statement, Tissue, Health assessment, Fatigue, American College of Rheumatology, ACR, Arthritis, Psoriasis, KDA, Quality of life, Private Securities Litigation Reform Act, Inflammatory arthritis, Swelling, Pharmaceutical industry, Oyster, Medical imaging, Vaccine, Sanofi, Ablynx

Sonelokimab (M1095) is an investigational Nanobody designed to treat inflammatory disease by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.

Key Points: 
  • Sonelokimab (M1095) is an investigational Nanobody designed to treat inflammatory disease by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
  • The ARGO study (M1095-PSA-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody sonelokimab, administered subcutaneously, in the treatment of adult patients with active psoriatic arthritis.
  • The study will comprise approximately 200 patients, and will evaluate different doses of sonelokimab, with placebo control and adalimumab as an active reference arm.
  • MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody for the treatment of inflammatory disease, to revolutionize outcomes for patients.

TNF Alpha Inhibitors Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 1, 2022
Health, Pharmaceutical, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Certolizumab pegol, Warfarin necrosis, Etanercept, IBD, Immune-mediated inflammatory diseases, Inflammation, Infliximab, Tuberculosis, UC, TNF, Dermatology, Food, Blastomycosis, Rheumatoid arthritis, Janssen Biotech, Crohn's disease, Ulcerative colitis, Tumor necrosis factor, Histoplasmosis, AbbVie, Disease, Inflammatory bowel disease, Rheumatology, Person, Eastman Kodak Co. v. Image Technical Services, Inc., Gastroenterology, Pfizer, Ankylosing spondylitis, Hepatitis, Candidiasis, RA, TNA, FDA, Spondyloarthropathy, Patient, Psoriasis, Adalimumab, Overalls, Growth, Infection, Neutropenia, Amgen, Prevalence, UCB, Pharmaceutical industry, Lithium, Ablynx

The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering.
  • The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-a) inhibitors by entities that manufacture TNF alpha inhibitors.
  • The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market.
  • Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion